Results 91 to 100 of about 77,108 (288)

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data

Diagnostics, 2018
Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone.
Theodoros G. Soldatos, Antonia Dimitrakopoulou-Strauss, Lionel Larribere, Jessica C. Hassel, Christos Sachpekidis   +4 more
doaj   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. [PDF]

, 2020
The role of palliative surgery in the management of acute complications in patients with disseminated malignancy remains controversial given the complexity of assessing acute surgical risk and long-term oncologic outcome. With the emergence of checkpoint
Bold, Richard J, Canter, Robert J, Cho, May, Fakih, Marwan, Gangi, Alexandra, Gholami, Sepideh, Gong, Jun, Ji, Jingran, Judge, Sean J, Kaur, Manmeet, Kim, Edward, Kirane, Amanda R, Liu, James, Tam, Kit W   +13 more
core  

Characterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021

International Journal of Cancer, EarlyView.
What's New? Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.
Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner   +10 more
wiley   +1 more source

Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to IMDC risk criteria—A multi‐center retrospective analysis on behalf of the GUARDIANS group

International Journal of Cancer, EarlyView.
What's New? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack   +21 more
wiley   +1 more source

Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment

Case Reports in Oncology, 2017
Until a few years ago, metastatic melanoma had a poor prognosis with limited treatment options. These therapeutics options and thereby median survival have increased obviously over 5 years with the arrival of immunotherapeutic drugs like ipilimumab ...
Lieke van Montfort, Caroline M. Loos, Monique Anten, Rob L.H. Jansen   +3 more
doaj   +1 more source

Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

Journal for ImmunoTherapy of Cancer
Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology.
David P. Carbone, T. Ciuleanu, M. Schenker, M. Cobo, S. Bordenave, Ó. Juan-Vidal, J. Menezes, N. Reinmuth, E. Richardet, Ying Cheng, H. Mizutani, E. Felip, B. Żurawski, A. Alexandru, L. Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Javed Mahmood, Nan Hu, Tuli De, Irene Santi, J. Penrod, Yong Yuan, Adam Lee, Martin Reck   +25 more
semanticscholar   +1 more source

Organ‐sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making

International Journal of Cancer, EarlyView.
Abstract Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumor types and confers a characteristic microsatellite instability‐high (MSI‐H) molecular phenotype. The MSI‐H/dMMR phenotype may arise from an inherited pathogenic variant in the context of Lynch syndrome and is most frequently observed in ...
Martin Duval, Antoine Dardenne, Thomas Samaille, Leo Mas, Jérémie H. Lefèvre, Xavier Dray, Mathilde Wagner, Romain Cohen, Thierry André   +8 more
wiley   +1 more source

Local Delivery of CTLA-4 Blockade Inhibits Growth of Pancreatic Tumors [PDF]

, 2016
Immune checkpoint blockade has demonstrated great potential in activating antitumor immunity. Ipilimumab is a monoclonal antibody which targets cytotoxic T-lymphocyte antigen-4. CTLA-4 belongs to the CD28 class of receptors and is found on the surface of
Baltz, Jack
core   +2 more sources